Common use of Agreement Preamble Clause in Contracts

Agreement Preamble. Alliance Manager Section 3.3(a) Arbitral Decision Section 14.2(b) Claims Section 12.1 Clinical Agreement Section 5.4 Commercialization Plan Section 6.2 Common Stock Section 8.3 Company Preamble CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH THREE ASTERISKS (***), HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. Company Board Section 11.6(c) Company Development Activities Section 5.4 Company Development Expenses Section 5.7(a) Company Indemnitees Section 12.1 Confidential Information Section 11.1 Co-Promotion Agreement Section 6.6 Co-Promotion Right Section 6.6 DoJ Section 16.19(a) Effective Date Section 14.1 Exchange Act Section 11.4(c) Execution Date Preamble Existing Inventory Section 7.3(a) Existing Regulatory Documentation Section 13.2(k) Existing Study Section 5.3(a) Facility Section 7.1(b) First Indications Section 5.3(a) FTC Section 16.19(a) Generic Market Data Section 8.7(c)(i(3) HSR Conditions Section 16.19(b) IMMU-132 Information Section 11.1 Indemnitee Section 12.3 Indemnitor Section 12.3 JCC Section 3.2 JDC Section 3.2 Joint Inventions Section 10.1 Joint Patents Section 10.3(c) JPC Section 3.2 JSC Section 3.1(a) Legal Proceeding Section 16.20 Letter Agreement Section 16.6 Licensee Preamble Licensee Indemnitees Section 12.2 Licensee Xxxx(s) Section 14.5(d) Losses Section 12.1 Manufacturing Agreements Section 7.3(d) Marks Section 10.8(a) Match Period Section 11.6(b) Milestone Event Section 8.4 New Affiliate Date Section 2.11 No-Shop Start Date Section 11.6(a) NSCLC Section 5.3(a) Other Licensed Molecule Section 2.10 Other Royalty Term Section 8.7(b)(ii) CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH THREE ASTERISKS (***), HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. Parties Preamble Party Preamble Product Infringement Section 10.4(a) Publication Section 11.5 Purchased Shares Section 8.3 Qualifying Sublicensee Section 8.2(a) Reimbursable Costs Section 16.20 ROFN Election Notice Section 2.9 ROFN Notice Section 2.9 ROFN Product Section 2.9 Sale of the Company Proposal Section 11.6(c) SCLC Section 5.3(a) Sole Inventions Section 10.1

Agreement Preamble. Alliance Manager Section 3.3(a3.1 Anti-Corruption Laws 12.7(a)(i) Arbitral Decision Section 14.2(bAudited Party 9.10(b)(i) Auditing Party 9.10(b)(i) Breach Notification 15.2(b)(i) BTC Data Package 1.65 Claims Section 12.1 13.1 Clinical Supply Agreement Section 5.4 7.3(b) CMO 7.2 Commercial Supply Agreement 7.3(c) Commercialization Plan Section 6.2 Common Stock Section 8.3 Company Preamble CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH THREE ASTERISKS (***), HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. Company Board Section 11.6(cMilestone Event 9.4 Commercialization Milestone Payment 9.4 Commitments Log 4.1 Confidentiality Agreement 17.11 Continuing Technology Transfer 4.1 Disclosing Party 1.21 Dispute 17.5(a) Company Development Activities Section 5.4 Company Development Expenses Section 5.7(aDMF 6.3 DOJ 16.2(a) Company Indemnitees Section 12.1 Confidential Information Section 11.1 Co-Promotion Agreement Section 6.6 Co-Promotion Right Section 6.6 DoJ Section 16.19(a) Effective Date Section 14.1 Exchange Act Section 11.4(cExcluded Claim 1.1(e) Execution Date Preamble Existing Inventory Section 7.3(aExecutive Officers 17.5(a) Executive Sponsors 3.2(f) Existing Regulatory Documentation Section 13.2(kMaterials 12.2(s) Existing Study Section 5.3(a) Facility Section 7.1(bEx-Territory Infringement 14.4(a) First Indications Section 5.3(aBLA 6.2(b) FTC Section 16.19(a16.2(b) Generic Market Data Section 8.7(c)(i(3Global Brand Elements 8.3(c) HSR Conditions Section 16.19(bFiling 16.1(a) IMMU-132 Information Section 11.1 Indemnitee Section 12.3 Indemnitor Section 12.3 JCC Section 3.2 JDC Section 3.2 ICH Guidelines 1.37 Indemnified Party 13.3 Indemnifying Party 13.3 Initial Technology Transfer 4.1 Jazz Preamble Jazz Collaboration IP 14.1(a) Jazz Collaboration Patent Rights 14.3(d) Jazz Competing Product 1.1(a) Jazz Indemnitee(s) 13.2 Jazz Publication 11.1(b) Joint Inventions Section 10.1 Collaboration IP 14.1(a) Joint Patents Section 10.3(cPatent Rights 14.1(d) JPC Section 3.2 JSC Section 3.1(a3.2(a) Legal Proceeding Section 16.20 Letter Agreement Section 16.6 Licensee Preamble Licensee Indemnitees Section 12.2 Licensee Xxxx(s) Section 14.5(dLicense 2.1(b) Losses Section 12.1 13.1 Manufacturing Agreements Section 7.3(dTechnology Transfer 7.2 Manufacturing Technology Transfer Plan 7.2 Manufacturing Transition Date 7.3(a) Marks Section 10.8(aManufacturing Working Group 3.2(g)(ii) Match Negotiation Period Section 11.6(b2.8 Notice of Dispute 17.5(a) Milestone Event Section 8.4 New Affiliate Date Section 2.11 No-Shop Start Date Section 11.6(a) NSCLC Section 5.3(a) Other Licensed Molecule Section 2.10 Other Royalty Term Section 8.7(b)(ii) CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH THREE ASTERISKS (***), HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. Offered Rights 2.8 Parties Preamble Party Preamble Patent Liaison 14.2 [*** ***] Post-Approval Commitments 6.7(b) PPQ 7.4(a) Product Infringement Section 10.4(a14.4(a) Product Marks 14.9(a) Public Official 12.7(d) Publication Section 11.5 Purchased Shares Section 8.3 Qualifying Sublicensee Section 8.2(a11.1(c) Reimbursable Costs Section 16.20 ROFN Election Notice Section 2.9 ROFN Notice Section 2.9 ROFN Quality Technical Agreement 7.3(d) Receiving Party 1.21 Regulatory Milestone Event 9.3 Regulatory Milestone Payment 9.3 Regulatory Working Group 3.2(g)(iii) Request Period 2.8 Review Period 11.1(b) Royalty Floor 9.6(c)(iii) Royalty Term 9.6(b) Safety Working Group 3.2(g)(iv) SDEA Agreement 6.4 SEC 11.3(c) Second Payment 9.1(b) Second Payment Due Date 9.1(b) Second Request 16.1(b) Securities Regulators 11.3(c) Technology Transfer 4.1 Term 15.1 Territory Development Plan 5.4 Upfront Payment 9.1(a) Western Europe 1.60 Working Group 3.2(g)(i) [*** ***] Zanidatamab 1.50 Zymeworks Preamble Zymeworks Collaboration IP 14.1(a) Zymeworks Competing Product Section 2.9 Sale of the Company Proposal Section 11.6(c1.1(b) SCLC Section 5.3(aZymeworks Development Plan 5.2(a) Sole Inventions Section 10.1Zymeworks Domain Names 14.9(b)(v) Zymeworks Indemnitee(s) 13.1 Zymeworks Manufacturing IP 7.2 Zymeworks Platform Patents 1.79 Zymeworks Publication 11.1(c)

Agreement Preamble. Alliance Manager Section 3.3(a) Arbitral Decision Section 14.2(b) Claims Section 12.1 Clinical Agreement Section 5.4 Commercialization Plan Section 6.2 Common Stock Section 8.3 Company 2.1 Arising Core Adaptimmune Patents 9.8.3 Arising Core Universal Cells Patents 9.8.4 Astellas Preamble CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH THREE ASTERISKS (Audited Party 11.6 Base Product 1.69 [***), HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. Company Board Section 11.6(c] 1.113 Burdened Technology 3.3.3(a) Company Development Activities Section 5.4 Company Development Expenses Section 5.7(aBurdened Technology Clearance 3.3.3(b) Company Indemnitees Section 12.1 Confidential Information Section 11.1 Burdened Technology Limitations 3.3.3(a) Ceasing Party 13.5.3 Co-Promotion Agreement Section 6.6 Commercialization Budget 6.2 Co-Promotion Right Section 6.6 DoJ Section 16.19(aDevelopment Budget 5.1 Collaboration Joint Patent Rights 9.8.5 Collaboration Profit-Share Target 4.10.2 Collaboration Research Plan Budget 4.1 Collaboration Research Program Opt-Out Notice 4.11 Collaboration Substitution Target 4.6.1 Combination Product 1.69 Co-Medical Affairs Plan 2.5.2(a) Commercialization Agreement 6.3 Competitive Activities 10.3 Continuing Development and Commercialization Notice 4.10.1 Continuing Party 13.5.3 Contributed Technology 3.5 Contributed Technology Dispute Notice 3.5 Contributed Technology Notice 3.5 Defending Party 9.10.1 Disputed Contributed Technology 3.5 Early Continuation Notice 4.11 Effective Date Section 14.1 Exchange Act Section 11.4(c) Execution Date Preamble Existing Inventory Section 7.3(aElected Unilateral Adaptimmune Product License 9.2.1 Elected Unilateral Adaptimmune Target 9.2.1 Elected Universal Cells Program Product License 9.2.2 Elected Universal Cells Program Target 9.2.2 Enforcing Party 9.9.7 Excluded Target Clearance 3.3.1 Executive Resolution Matters 2.2.4(b) Existing Regulatory Documentation Section 13.2(k) Existing Study Section 5.3(a) Facility Section 7.1(b) Agreement Preamble First Indications Section 5.3(a) FTC Section 16.19(a) Generic Market Data Section 8.7(c)(i(3) HSR Conditions Section 16.19(b) IMMU-132 Information Section 11.1 Collaboration Target Nomination Date 3.2.1 Indemnitee Section 12.3 16.3 Indemnitor Section 12.3 16.3 Indirect Taxes 11.9.2 JCC Section 3.2 2.7.1 JDC Section 3.2 Joint Inventions Section 10.1 Joint Patents Section 10.3(c) JPC Section 3.2 2.4.1 JFC 2.6.1 JMAC 2.5.1 JRC 2.3.1 JSC Section 3.1(a) Legal Proceeding Section 16.20 Letter Agreement Section 16.6 Licensee Preamble Licensee Indemnitees Section 12.2 Licensee Xxxx(s) Section 14.5(d) 2.2.1 Lapsed Target 4.10.4 Licensed Unilateral Universal Cells Product Patent 1.104 Losses Section 12.1 Manufacturing Agreements Section 7.3(d) Marks Section 10.8(a) Match Period Section 11.6(b) Milestone Event Section 8.4 New Affiliate Date Section 2.11 No16.1 Non-Shop Start Date Section 11.6(a) NSCLC Section 5.3(a) Excluded Target 1.44 Non-Publishing Party 12.6.3 Opt-Out Notice 5.3 Other Licensed Molecule Section 2.10 Other Royalty Term Section 8.7(b)(ii) CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH THREE ASTERISKS (***), HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. Component 1.69 Parties Preamble Party Preamble Phase 1 Data Availability Date 4.10.1 Phase 1 Success Criteria 4.1 Publishing Party 12.6.3 Qualifying Adaptimmune Change of Control 17.2.3 Qualifying Adaptimmune CoC Notice 17.2.3(a) Royalty Conversion Payments 17.2.3(f) Rules 14.2.1 Sale Transaction 17.2.1 Second Collaboration Target Nomination Date 3.2.1 Selling Party 1.69 Target Substitution Right 4.6.1 Term 13.1 Third Collaboration Target Nomination Date 3.2.1 Third Party Acquirer 17.2.2(a) Third Party Claim 16.1 Third Party License 11.4.6(b) Unilateral Adaptimmune Product Infringement Section 10.4(aElected License Notice 9.2.1 Unilateral Adaptimmune Product-Specific Collaboration Joint Patent Rights 9.9.5(d) Publication Section 11.5 Purchased Shares Section 8.3 Qualifying Sublicensee Section 8.2(aUnilateral Adaptimmune Product-Specific Patents 9.8.6 Unilateral Adaptimmune Target 4.10.3(b) Reimbursable Costs Section 16.20 ROFN Unilateral Universal Cells Product-Specific Patents 9.8.7 Universal Cells Preamble Universal Cells Acquiree 17.2.2(a) Universal Cells Acquisition 17.2.2(a) Universal Cells Background Patents 9.8.2 Universal Cells Election Period 9.2.1 Universal Cells Impediment 3.5 Universal Cells Indemnified Parties 16.1 Universal Cells Program 8.2 Universal Cells Program Product Elected License Notice Section 2.9 ROFN Notice Section 2.9 ROFN Product Section 2.9 Sale of the Company Proposal Section 11.6(c) SCLC Section 5.3(a) Sole Inventions Section 10.19.2.2 Universal Cells Research Activities 8.1 Universal Cells Substitution Target 4.6.1 Withholding Party 11.9.1

Agreement Preamble. Alliance Manager Section 3.3(aAnnual Royalty Cap 4.5.1(b) Arbitral Decision Section 14.2(bBBA LIBOR 1.47 “[***]” Preamble “[***]” Indemnitees 10.2 Claim 10.1 Clinical Collaboration Product Supply 3.3.5 Combination Product 1.53 Commercial Period 3.1 Commercial Period Milestone Event 4.4.1 Commercial Period Milestone Payment 4.4.1 Commercial Supply Agreement 3.3.6(b) Claims Section 12.1 Clinical Agreement Section 5.4 Commercialization Plan Section 6.2 Common Stock Section 8.3 Company “[***]” Preamble CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN Effective Date Preamble Failure of PART B Deliverables 2.3.2(b) Field Expansion 2.5 FCPA 9.2.15 Gross Sales 1.53 Indemnified Party 10.3 Indemnifying Party 10.3 Infringement 7.2.1 Infringement Notice 7.2.1 Insolvency Event 8.2.4 NOTE: PORTIONS OF THIS DOCUMENTEXHIBIT ARE THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST BY THE REGISTRANT TO THE SECURITIES AND EXCHANGE COMMISSION (“COMMISSION”). EACH SUCH PORTION, WHICH HAS PORTIONS HAVE BEEN OMITTED HEREIN REDACTED AND REPLACED WITH THREE ASTERISKS (***), HAS BEEN FILED SEPARATELY WITH THE SECURITIES COMMISSION AND EXCHANGE COMMISSION. Company Board Section 11.6(c) Company Development Activities Section 5.4 Company Development Expenses Section 5.7(a) Company Indemnitees Section 12.1 Confidential Information Section 11.1 Co-Promotion Agreement Section 6.6 Co-Promotion Right Section 6.6 DoJ Section 16.19(a) Effective Date Section 14.1 Exchange Act Section 11.4(c) Execution Date Preamble Existing Inventory Section 7.3(a) Existing Regulatory Documentation Section 13.2(k) Existing Study Section 5.3(a) Facility Section 7.1(b) First Indications Section 5.3(a) FTC Section 16.19(a) Generic Market Data Section 8.7(c)(i(3) HSR Conditions Section 16.19(b) IMMU-132 Information Section 11.1 Indemnitee Section 12.3 Indemnitor Section 12.3 JCC Section 3.2 JDC Section 3.2 Joint Inventions Section 10.1 Joint Patents Section 10.3(c) JPC Section 3.2 JSC Section 3.1(a) Legal Proceeding Section 16.20 Letter Agreement Section 16.6 Licensee Preamble Licensee Indemnitees Section 12.2 Licensee Xxxx(s) Section 14.5(d) Losses Section 12.1 Manufacturing Agreements Section 7.3(d) Marks Section 10.8(a) Match Period Section 11.6(b) Milestone Event Section 8.4 New Affiliate Date Section 2.11 No-Shop Start Date Section 11.6(a) NSCLC Section 5.3(a) Other Licensed Molecule Section 2.10 Other Royalty Term Section 8.7(b)(ii) CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED ARE MARKED WITH THREE ASTERISKS (A “[***), HAS BEEN FILED SEPARATELY WITH ]” IN PLACE OF THE SECURITIES AND EXCHANGE COMMISSIONREDACTED LANGUAGE. Intec Pharma Preamble Intec Pharma Indemnitees 10.1 Intec Pharma-Owned Technology 9.2.12 License Fee 4.2 Losses 10.1 Manufacturing Know-How 3.3.7 Option 2.4.2 Option Exercise Date 2.4.2 Option Exercise Notice 2.4.2 Option Exercise Period 2.4.1 PART A Deliverables 2.3.2(a) PART B Deliverables 2.3.2(b) PART B Election Notice 2.3.2(a) Party/Parties Preamble Party Preamble Product Infringement Section 10.4(aPatent Coordinator 6.5 Phase 1 Clinical Trial Materials 2.3.2(b) Publication Section 11.5 Purchased Shares Section 8.3 Qualifying Sublicensee Section 8.2(aPhase 1 Materials Acceptance Date 2.3.2(b) Reimbursable Costs Section 16.20 ROFN Election Pre-Commercialization Collaboration Notice Section 2.9 ROFN Notice Section 2.9 ROFN Product Section 2.9 Sale of the Company Proposal Section 11.6(c) SCLC Section 5.3(a) Sole Inventions Section 10.13.3.2 Pre-Commercialization Plan 3.3.2 Research Period 2.1 Research Period Milestone Event 4.3.1 Research Period Milestone Payment 4.3.1 Sunshine Act 9.2.15 Technology Transfer 3.3.7 Term 8.1 U.S. GAAP 1.53 UK Bribery Act 9.2.15

Agreement Preamble. Alliance Manager Section 3.3(aAnnual Royalty Cap 4.5.1(b) Arbitral Decision Section 14.2(bBBA LIBOR 1.47 Biogen Preamble Biogen Indemnitees 10.2 Claim 10.1 Clinical Collaboration Product Supply 3.3.5 Combination Product 1.53 Commercial Period 3.1 Commercial Period Milestone Event 4.4.1 Commercial Period Milestone Payment 4.4.1 Commercial Supply Agreement 3.3.6(b) Claims Section 12.1 Clinical Agreement Section 5.4 Commercialization Plan Section 6.2 Common Stock Section 8.3 Company “[***]” Preamble CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN Effective Date Preamble Failure of PART B Deliverables 2.3.2(b) Field Expansion 2.5 FCPA 9.2.15 Gross Sales 1.53 Indemnified Party 10.3 Indemnifying Party 10.3 Infringement 7.2.1 Infringement Notice 7.2.1 Insolvency Event 8.2.4 NOTE: PORTIONS OF THIS DOCUMENTEXHIBIT ARE THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST BY THE REGISTRANT TO THE SECURITIES AND EXCHANGE COMMISSION (“COMMISSION”). EACH SUCH PORTION, WHICH HAS PORTIONS HAVE BEEN OMITTED HEREIN REDACTED AND REPLACED WITH THREE ASTERISKS (***), HAS BEEN FILED SEPARATELY WITH THE SECURITIES COMMISSION AND EXCHANGE COMMISSION. Company Board Section 11.6(c) Company Development Activities Section 5.4 Company Development Expenses Section 5.7(a) Company Indemnitees Section 12.1 Confidential Information Section 11.1 Co-Promotion Agreement Section 6.6 Co-Promotion Right Section 6.6 DoJ Section 16.19(a) Effective Date Section 14.1 Exchange Act Section 11.4(c) Execution Date Preamble Existing Inventory Section 7.3(a) Existing Regulatory Documentation Section 13.2(k) Existing Study Section 5.3(a) Facility Section 7.1(b) First Indications Section 5.3(a) FTC Section 16.19(a) Generic Market Data Section 8.7(c)(i(3) HSR Conditions Section 16.19(b) IMMU-132 Information Section 11.1 Indemnitee Section 12.3 Indemnitor Section 12.3 JCC Section 3.2 JDC Section 3.2 Joint Inventions Section 10.1 Joint Patents Section 10.3(c) JPC Section 3.2 JSC Section 3.1(a) Legal Proceeding Section 16.20 Letter Agreement Section 16.6 Licensee Preamble Licensee Indemnitees Section 12.2 Licensee Xxxx(s) Section 14.5(d) Losses Section 12.1 Manufacturing Agreements Section 7.3(d) Marks Section 10.8(a) Match Period Section 11.6(b) Milestone Event Section 8.4 New Affiliate Date Section 2.11 No-Shop Start Date Section 11.6(a) NSCLC Section 5.3(a) Other Licensed Molecule Section 2.10 Other Royalty Term Section 8.7(b)(ii) CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED ARE MARKED WITH THREE ASTERISKS (A “[***), HAS BEEN FILED SEPARATELY WITH ]” IN PLACE OF THE SECURITIES AND EXCHANGE COMMISSIONREDACTED LANGUAGE. Intec Pharma Preamble Intec Pharma Indemnitees 10.1 Intec Pharma-Owned Technology 9.2.12 License Fee 4.2 Losses 10.1 Manufacturing Know-How 3.3.7 Option 2.4.2 Option Exercise Date 2.4.2 Option Exercise Notice 2.4.2 Option Exercise Period 2.4.1 PART A Deliverables 2.3.2(a) PART B Deliverables 2.3.2(b) PART B Election Notice 2.3.2(a) Party/Parties Preamble Party Preamble Product Infringement Section 10.4(aPatent Coordinator 6.5 Phase 1 Clinical Trial Materials 2.3.2(b) Publication Section 11.5 Purchased Shares Section 8.3 Qualifying Sublicensee Section 8.2(aPhase 1 Materials Acceptance Date 2.3.2(b) Reimbursable Costs Section 16.20 ROFN Election Pre-Commercialization Collaboration Notice Section 2.9 ROFN Notice Section 2.9 ROFN Product Section 2.9 Sale of the Company Proposal Section 11.6(c) SCLC Section 5.3(a) Sole Inventions Section 10.13.3.2 Pre-Commercialization Plan 3.3.2 Research Period 2.1 Research Period Milestone Event 4.3.1 Research Period Milestone Payment 4.3.1 Sunshine Act 9.2.15 Technology Transfer 3.3.7 Term 8.1 U.S. GAAP 1.53 UK Bribery Act 9.2.15